
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded orally dissolving tablet containing acetazolamide, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing acetazolamide are listed in tablet, capsule and injection forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, edema, certain epilepsies and altitude sickness; compounded oral suspensions are made to a prescriber's order.
Acetazolamide is a nonbacteriostatic sulfonamide that inhibits carbonic anhydrase. In the eye this lowers aqueous humor secretion and intraocular pressure; in the kidney it increases loss of bicarbonate with sodium, water and potassium. Acetazolamide tablets and injection are FDA-approved as adjunctive treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies, and open-angle, secondary and preoperative acute angle-closure glaucoma, and for prevention or amelioration of acute mountain sickness symptoms; the extended-release capsules carry the glaucoma and acute mountain sickness indications. A prescriber might order acetazolamide compounded as an oral liquid for patients who cannot swallow tablets; a published stability study examined an acetazolamide suspension compounded from tablets. Compounded preparations are not FDA-approved and require a prescription.
Acetazolamide is a sulfonamide. Fatal reactions to sulfonamides, though rare, have occurred, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood disorders, and anaphylaxis; stop it and get help for rash, fever, sore throat or unusual bleeding. Do not use it if you have low sodium or potassium, marked kidney or liver disease, cirrhosis, adrenal gland failure, hyperchloremic acidosis, or chronic noncongestive angle-closure glaucoma (for long-term use). Use with high-dose aspirin has caused acidosis, coma and death. It raises phenytoin levels, can lower primidone levels, can change blood sugar, and should not be combined with other carbonic anhydrase inhibitors. It can cause drowsiness, fatigue and nearsightedness that may affect driving. Animal studies showed limb defects; use in pregnancy only if benefit justifies risk. Low levels pass into breast milk. Talk to your prescriber or pharmacist about tingling, appetite loss or other side effects.
Acetazolamide inhibits carbonic anhydrase, reducing aqueous humor formation, producing renal bicarbonate loss with alkaline urine and diuresis, and appearing to retard paroxysmal neuronal discharge in the CNS. StatPearls describes it as well absorbed, concentrated in kidneys and red blood cells by carbonic anhydrase binding, not metabolized, and renally excreted with a half-life of 6 to 9 hours. Labeled indications are described above for the tablets, extended-release capsules and injection. Alexander and colleagues (Am J Hosp Pharm, 1991) reported an acetazolamide suspension compounded from tablets stable for at least 79 days at refrigerated and room temperatures in amber glass, and recommended pH 4 to 5; compounded oral liquids are not an FDA-approved dosage form. Dosing is per prescriber. Per the label, obtain a baseline CBC and platelet count and repeat at regular intervals, and monitor serum electrolytes periodically, with particular caution in renal impairment, older adults, diabetes and impaired alveolar ventilation; severe metabolic acidosis may occur in older patients with reduced renal function. Growth retardation has been reported in children on long-term therapy. Acetazolamide is not a controlled substance.
Wash and dry your hands first. Place the tablet on or under your tongue, or between your cheek and gum if your label says so, and let it dissolve. Do not chew or swallow it whole unless directed. Dissolving usually takes up to a minute. Follow your label for timing around food and drink.
These tablets are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Keep them in the closed container at room temperature, away from moisture and heat, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 tablet under the tongue and let dissolve before swallowing. Do not chew.